Ted Yednock, Ph.D., currently holds the position of Executive Vice President and Chief Innovation Officer at ANNEXON INC, a biopharmaceutical company focused on developing novel therapies for autoimmune and neurodegenerative diseases. In his role, Dr. Yednock is responsible for overseeing the company's research and development efforts, as well as driving innovation and strategic growth. His expertise in drug discovery and development has been instrumental in advancing ANNEXON's pipeline of potential treatments. Prior to joining ANNEXON, Dr. Yednock had a distinguished career in the biopharmaceutical industry, with over 30 years of experience in research and development. He previously served as Senior Vice President and Chief Scientific Officer at Elan Pharmaceuticals, where he played a key role in the development of Tysabri, a breakthrough treatment for multiple sclerosis. Dr. Yednock's scientific contributions have been recognized through numerous patents and publications in prestigious scientific journals. He holds a Ph.D. in Immunology from the University of California, Berkeley, and completed his postdoctoral training at the National Institutes of Health. As Chief Innovation Officer at ANNEXON, Dr. Yednock leads a team of talented scientists and researchers in the discovery and development of novel therapeutics targeting the complement system. His leadership and vision have been crucial in advancing the company's lead candidate, ANX005, into clinical trials for the treatment of Guillain-Barré Syndrome. Under Dr. Yednock's guidance, ANNEXON continues to expand its research efforts into other complement-mediated diseases, with the goal of bringing transformative therapies to patients in need.